Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. – 94. (Canceled)

95. (Previously presented) A crystal of infliximab, wherein the crystal comprises infliximab, ethoxyethanol, lithium sulfate, and Tris buffer.

96. (Previously presented) The crystal of claim 95, wherein the pH of the Tris buffer is 8.6.

97. (Previously presented) A method of crystallizing infliximab, the method comprising:

combining infliximab, ethoxyethanol, lithium sulfate, and Tris buffer, thereby forming a crystallization solution; and

incubating the crystallization solution, thereby crystallizing infliximab.

98. (Previously presented) The method of claim 97, wherein the method is performed at room temperature.

99. (Previously presented) The method of claim 97, wherein the method is performed at pH 8.6.

100. (Previously presented) The method of claim 97, wherein the concentration of infliximab in the crystallization solution is $\frac{2.5}{0.15}$ mg/ml.

101. (Previously presented) The method of claim 97, wherein the percentage of ethoxyethanol in the crystallization solution is $\frac{3500}{150}\%$.

102. (Previously presented) The method of claim 97, wherein the concentration of lithium sulfate in the crystallization solution is $\frac{20}{150}$ M.

103. (Previously presented) The method of claim 97, wherein the concentration of Tris buffer in the crystallization solution is $\frac{10}{150}$ M.

104. (Previously presented) The method of claim 97, wherein the concentration of infliximab in the crystallization solution is $\frac{2.5}{0.15}$ mg/ml, the percentage of ethoxyethanol in the crystallization solution is $\frac{3500}{150}\%$, the concentration of lithium sulfate in the crystallization solution is $\frac{20}{150}$M, and the concentration of Tris buffer in the crystallization solution is $\frac{10}{150}$ M.

105. (Previously presented) A crystal of infliximab, wherein the crystal comprises infliximab, PEG-400, lithium sulfate, and Tris buffer.

106. (Previously presented) The crystal of claim 105, wherein the pH of the Tris buffer is 8.5.

107. (Previously presented) A method of crystallizing infliximab, the method comprising:

combining infliximab, PEG-400, lithium sulfate, and Tris buffer, thereby forming a crystallization solution; and

incubating the crystallization solution, thereby crystallizing infliximab.

108. (Previously presented) The method of claim 107, wherein the method is performed at room temperature.

109. (Previously presented) The method of claim 107, wherein the method is performed at pH 8.5.

110. (Previously presented) The method of claim 107, wherein the concentration of infliximab in the crystallization solution is $\frac{2.5}{0.15}$ mg/ml.

111. (Previously presented) The method of claim 107, wherein the percentage of PEG-400 in the crystallization solution is $\frac{4000}{150}\%$.

112. (Previously presented) The method of claim 107, wherein the concentration of lithium sulfate in the crystallization solution is $\frac{20}{150}$ M.

113. (Previously presented) The method of claim 107, wherein the concentration of Tris buffer in the crystallization solution is $\frac{10}{150}$ M.

114. (Previously presented) The method of claim 107, wherein the concentration of infliximab in the crystallization solution is $\frac{2.5}{0.15}$ mg/ml, the percentage of PEG-400 in the crystallization solution is $\frac{4000}{150}\%$, the concentration of lithium sulfate in the crystallization solution is $\frac{20}{150}$ M, and the concentration of Tris buffer in the crystallization solution is $\frac{10}{150}$ M.

115. (Previously presented) A crystal of infliximab, wherein the crystal comprises infliximab, polyethylene glycol monomethyl ether 550 (PEG MME 550), calcium chloride, and Tris HCl buffer.

116. (Previously presented) The crystal of claim 115, wherein the pH of the Tris HCl buffer is 7.0.

117. (Previously presented) A method of crystallizing infliximab, the method comprising:

combining infliximab, PEG MME 550, calcium chloride, and Tris HCl buffer, thereby forming a crystallization solution; and

incubating the crystallization solution, thereby crystallizing infliximab.

118. (Previously presented) The method of claim 117, wherein the method is performed at room temperature.

119. (Previously presented) The method of claim 117, wherein the pH of the Tris HCl buffer is 7.0.

120. (Previously presented) The method of claim 117, wherein the concentration of infliximab in the crystallization solution is $\frac{1.25}{0.033}$ mg/ml.

121. (Previously presented) The method of claim 117, wherein the percentage of PEG MME 550 in the crystallization solution is $\frac{500}{33}\%$.

122. (Previously presented) The method of claim 117, wherein the concentration of calcium chloride in the crystallization solution is $\frac{3}{33}$ M.

123. (Previously presented) The method of claim 117, wherein the concentration of Tris HCl buffer in the crystallization solution is $\frac{2.5}{33}$ M.

124. (Previously presented) The method of claim 117, wherein the concentration of infliximab in the crystallization solution is $\frac{1.25}{0.033}$ mg/ml, the percentage of PEG MME 550 in the crystallization solution is $\frac{500}{33}\%$, the concentration of calcium chloride in the crystallization solution is $\frac{3}{33}$ M, and the concentration of Tris HCl buffer in the crystallization solution is $\frac{2.5}{33}$ M.

125. (Previously presented) A crystal of infliximab, wherein the crystal comprises infliximab, PEG 300, Tris buffer, PEG 8000, and glycerol.

126. (Previously presented) The crystal of claim 125, wherein the pH of the Tris buffer is 8.5.

127. (Previously presented) A method of crystallizing infliximab, the method comprising:

combining infliximab, PEG 300, Tris buffer, PEG 8000, and glycerol, thereby forming a crystallization solution; and

incubating the crystallization solution, thereby crystallizing infliximab.

128. (Previously presented) The method of claim 127, wherein the method is performed at room temperature.

129. (Previously presented) The method of claim 127, wherein the pH is 8.5.

130. (Previously presented) The method of claim 127, wherein the concentration of infliximab in the crystallization solution is $\frac{0.5}{0.075}$ mg/ml.

131. (Previously presented) The method of claim 127, wherein the percentage of PEG 300 in the crystallization solution is $\frac{1000}{75}$%.

132. (Previously presented) The method of claim 127, wherein the concentration of Tris buffer in the crystallization solution is $\frac{5}{75}$ M.

133. (Previously presented) The method of claim 127, wherein the percentage of PEG 8000 in the crystallization solution is $\frac{250}{75}$%.

134. (Previously presented) The method of claim 127, wherein the percentage of glycerol in the crystallization solution is $\frac{500}{75}$%.

135. (Previously presented) The method of claim 127, wherein the concentration of infliximab in the crystallization solution is $\frac{0.5}{0.075}$ mg/ml, the percentage of PEG 300 in the crystallization solution is $\frac{1000}{75}$%, the concentration of Tris buffer in the crystallization solution

is $\frac{5}{75}$M, the percentage of PEG 8000 in the crystallization solution is $\frac{250}{75}$%, and the percentage of glycerol in the crystallization solution is $\frac{500}{75}$%.

136. – 138. (Canceled)